Unoprostone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Unoprostone
Unoprostone.svg
Clinical data
Trade namesRescula
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
Topical (eye drops)
ATC code
Legal status
Legal status
  • US: Discontinued
Pharmacokinetic data
Elimination half-life14 min
ExcretionRenal
Identifiers
  • (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)
    cyclopentyl]hept-5-enoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.227.145 Edit this at Wikidata
Chemical and physical data
FormulaC22H38O5
Molar mass382.541 g·mol−1
3D model (JSmol)
  • O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCC(=O)CCCCCCC
  • InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1 ☒N
  • Key:TVHAZVBUYQMHBC-SNHXEXRGSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]

It was approved by the Food and Drug Administration in 2000.[3]

In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]

In 2015, the drug was discontinued in the U.S.

References[edit]

  1. ^ Micromedex Detailed Consumer Information
  2. ^ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. Auckland, N.Z. 8: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
  3. ^ "Drug Approval Package". Food and Drug Administration.
  4. ^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.